Supernus Pharmaceuticals Has Granted Rights To Knight Therapeutic To Seek Regulatory Approval And Commercialize Qelbree In Canada For Attention-deficit Hyperactivity Disorder; Financial Terms Of The Agreement Were Not Disclosed
Portfolio Pulse from Benzinga Newsdesk
Supernus Pharmaceuticals has entered into an agreement with Knight Therapeutic, granting Knight the rights to seek regulatory approval and commercialize Qelbree in Canada for the treatment of ADHD. The financial terms of the agreement have not been disclosed.
December 19, 2023 | 12:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Supernus Pharmaceuticals has partnered with Knight Therapeutic for the Canadian market approval and commercialization of Qelbree, an ADHD treatment. The financial details remain undisclosed.
The partnership with Knight Therapeutic could open up a new market for Supernus Pharmaceuticals' Qelbree, potentially increasing its revenue stream. However, without financial details, the exact impact on the stock is uncertain, but it is generally positive news as it represents business growth.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 80